N-(4-(4-amino-2,5-difluorophenoxy)pyridin-2-yl)acetamide | 1426312-68-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(4-(4-amino-2,5-difluorophenoxy)pyridin-2-yl)acetamide
• 英文别名: N-[4-(4-amino-2,5-difluorophenoxy)pyridin-2-yl]acetamide
• CAS: 1426312-68-6
• 化学式: C₁₃H₁₁F₂N₃O₂
• 分子量: 279.246
• InChiKey: NVYIDTPVXTWOAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-fluoro-phenyl)-4-iodo-2-oxo-1,2-dihydro-pyridine-3-carbonyl chloride 、 N-(4-(4-amino-2,5-difluorophenoxy)pyridin-2-yl)acetamide 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4-fluorophenyl)-4-iodo-2-oxo-1,2-dihydropyridine-3-carboxylic acid [4-(2-acetylaminopyridin-4-yloxy)-2,5-difluorophenyl]amide
  参考文献：
  名称：

  [EN] PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
  [FR] AMIDES ET ANALOGUES DE PYRIDONE PRÉSENTANT DES ACTIVITÉS ANTICANCÉREUSES ET ANTIPROLIFÉRATIVES

  摘要：

  公开号：

  WO2013078295A3

文献信息

• PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
  申请人：Flynn Daniel L.

  公开号：US20130317066A1

  公开（公告）日：2013-11-28

  Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.

  公开了一种根据公式I用于治疗哺乳动物癌症，特别是人类癌症的化合物。还公开了使用此处公开的化合物的药物组合物和治疗方法。
• EP2782577A2
  申请人：——

  公开号：EP2782577A2

  公开（公告）日：2014-10-01
• US8921565B2
  申请人：——

  公开号：US8921565B2

  公开（公告）日：2014-12-30
• US9387202B2
  申请人：——

  公开号：US9387202B2

  公开（公告）日：2016-07-12
• [EN] OXETANE 3,3-DICARBOXAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS OXÉTANE-3,3-DICARBOXAMIDES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：NEW HOPE R & D BIOSCIENCE INC

  公开号：WO2013032797A2

  公开（公告）日：2013-03-07

  A novel series of oxetane 3,3-dicarboxamide compounds modulate protein kinase activity for modulating cellular activities such as proliferation, migration, differentiation, and programmed cell death. This novel series of oxetane 3,3-dicarboxamide compounds may inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDR (VEGFR-2) signal transduction pathways, thereby make them useful as anti-cancer agents. The pharmaceutical compositions that comprise these compounds are also useful in the treatment of diseases, other than cancers, which are associated with signal transduction pathways operating through growth factor and anti-angiogenesis receptors, such as c-Met, and KDR (VEGFR-2).